Fate Therapeutics announces resignation of CFO Edward Dulac (NASDAQ:FATE)


Multi ethnic research team studying DNA mutations. Female doctor in foreground

janiecbros/E+ via Getty Images

  • Fate Therapeutics (NASDAQ:FATE) disclosed on Friday that chief financial officer Edward Dulac will resign from the company, effective June 14.
  • FATE added that it plans to appoint Scott Wolchko, president and CEO, as the CFO, principal financial and accounting officer, effective immediately after Dulac’s resignation.

Source link

Leave A Reply

Your email address will not be published.